Casper Steenholdt

​​​​Title: MD, PhD

E-mail: Casper.steenholdt.02@regionh.dk

Address: Glostrup Hospital, Dept of Internal Medicine, Ndr. Ringvej 57, DK-2600 Glostrup, Denmark

Research

  • Personalized therapy with TNF-inhibitors in IBD
  • Quality of care parameters in anti-TNF therapy in IBD​
​​​​

​​​Keywords

  • IBD
  • Clinical
  • TNF-inhibitors
  • Personalized therapy​
​​​

Selected publications

  • Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011;46:310-318.
  • Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel diseas
  • e. Aliment Pharmacol Ther 2011; 34:51-58.
  • Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OØ, Ainsworth MA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2209-2217.
  • Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Thomsen OØ, J Seidelin. Outcome after discontinuing infliximab in patients with inflammatory bowel disease in clinical remission: An observational Danish single center study. Scand J Gastroenterol. 2012;47:518-527.
  • Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2012;36:650-659.
  • ​Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:1172-1183.
  • Steenholdt C, Ainsworth MA, Tovey M et al. Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease. Ther Drug Monit 2013;35:530-538.
  • Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J et al. Individualized therapy is more cost-effective than dose intensification in Crohn's disease patients who fail anti-TNF treatment: a randomized, controlled trial. Gut 2014;63:919-927.
  • Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post-hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014; 109:1055–1064.
  • Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OØ, Bendtzen K, Steenholdt C. Antibodies against infliximab (IFX) are associated with de novo development of antibodies to adalimumab (ADL) and therapeutic failure in IFX-to-ADL switchers with inflammatory bowel disease. Inflamm Bowel Dis 2014; jul 25. [Epub ahead of print]
​​​

​​Presentations

54 presentations (posters and oral lectures)​​


Education

1999​: Student at Birkerød Gymnasium, Denmark

2007: Medical Doctor (MD) at University of Copenhagen, Denmark

2009: Medical authorization

2013: PhD at Faculty of Health and Medical Sciences at the University of Copenhagen​


​​​​​Employment/professional experience

2007-09: Turnus (internship) at Holbæk Hospital

2009-12: PhD at Dept. of Gastroenterology, Medical Section, Herlev Hospital

2012: Dept. of Dermatology, Gentofte Hospital

2013: Dept. of Internal Medicine, Gentofte Hospital

2013: Post.doc. at Dept. of Gastroenterology, Herlev Hospital

2014: Dept. of Gastroenterology, Medical Section, Herlev Hospital

2014: Dept. of Internal Medicine, Glostrup Hospital (fellowship gastroenterology)​






Redaktør